How to buy Anika Therapeutics stock - 11 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Anika Therapeutics stock

Own Anika Therapeutics stock in just a few minutes.

Anika Therapeutics, Inc is a biotechnology business based in the US. Anika Therapeutics shares (ANIK) are listed on the NASDAQ and all prices are listed in US Dollars. Anika Therapeutics employs 277 staff and has a trailing 12-month revenue of around USD$130.5 million.

How to buy shares in Anika Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Anika Therapeutics. Find the stock by name or ticker symbol: ANIK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Anika Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Anika Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Anika Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Anika Therapeutics share price

Use our graph to track the performance of ANIK stocks over time.

Anika Therapeutics shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$27.535 - USD$47.475
50-day moving average USD$36.9646
200-day moving average USD$37.7851
Wall St. target priceUSD$48
PE ratio 43
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.793

Buy Anika Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Anika Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Anika Therapeutics under- or over-valued?

Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Anika Therapeutics's P/E ratio

Anika Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, Anika Therapeutics shares trade at around 43x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Anika Therapeutics's PEG ratio

Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1868. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Anika Therapeutics's EBITDA

Anika Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$14.8 million.

The EBITDA is a measure of a Anika Therapeutics's overall financial performance and is widely used to measure a its profitability.

Anika Therapeutics financials

Revenue TTM USD$130.5 million
Operating margin TTM 1.04%
Gross profit TTM USD$80.1 million
Return on assets TTM 0.24%
Return on equity TTM -8.55%
Profit margin -18.38%
Book value $19.01
Market capitalisation USD$563.2 million

TTM: trailing 12 months

Shorting Anika Therapeutics shares

There are currently 1.3 million Anika Therapeutics shares held short by investors – that's known as Anika Therapeutics's "short interest". This figure is 3.1% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Anika Therapeutics shares can be evaluated.

Anika Therapeutics's "short interest ratio" (SIR)

Anika Therapeutics's "short interest ratio" (SIR) is the quantity of Anika Therapeutics shares currently shorted divided by the average quantity of Anika Therapeutics shares traded daily (recently around 145231.41304348). Anika Therapeutics's SIR currently stands at 9.2. In other words for every 100,000 Anika Therapeutics shares traded daily on the market, roughly 9200 shares are currently held short.

However Anika Therapeutics's short interest can also be evaluated against the total number of Anika Therapeutics shares, or, against the total number of tradable Anika Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anika Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Anika Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Anika Therapeutics shares, roughly 111 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Anika Therapeutics.

Find out more about how you can short Anika Therapeutics stock.

Anika Therapeutics share dividends

We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.

Anika Therapeutics share price volatility

Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $27.535 up to $47.475. A popular way to gauge a stock's volatility is its "beta".

ANIK.US volatility(beta: 1.25)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 1.2515. This would suggest that Anika Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Anika Therapeutics overview

Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site